Anticancer Drugs: Recent Strategies to Improve Stability Profile,Pharmacokinetic and Pharmacodynamic Properties |
| |
Authors: | Giuseppina Ioele Martina Chieffallo Maria Antonietta Occhiuzzi Michele De Luca Antonio Garofalo Gaetano Ragno Fedora Grande |
| |
Affiliation: | Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy |
| |
Abstract: | In past decades, anticancer research has led to remarkable results despite many of the approved drugs still being characterized by high systemic toxicity mainly due to the lack of tumor selectivity and present pharmacokinetic drawbacks, including low water solubility, that negatively affect the drug circulation time and bioavailability. The stability studies, performed in mild conditions during their development or under stressing exposure to high temperature, hydrolytic medium or light source, have demonstrated the sensitivity of anticancer drugs to many parameters. For this reason, the formation of degradation products is assessed both in pharmaceutical formulations and in the environment as hospital waste. To date, numerous formulations have been developed for achieving tissue-specific drug targeting and reducing toxic side effects, as well as for improving drug stability. The development of prodrugs represents a promising strategy in targeted cancer therapy for improving the selectivity, efficacy and stability of active compounds. Recent studies show that the incorporation of anticancer drugs into vesicular systems, such as polymeric micelles or cyclodextrins, or the use of nanocarriers containing chemotherapeutics that conjugate to monoclonal antibodies can improve solubility, pharmacokinetics, cellular absorption and stability. In this study, we summarize the latest advances in knowledge regarding the development of effective highly stable anticancer drugs formulated as stable prodrugs or entrapped in nanosystems. |
| |
Keywords: | cancer therapy drug stability prodrugs vesicular systems nanoparticles trastuzumab |
|
|